Immunotherapy Revolutionizes Kidney Cancer Treatment, Offering Renewed Hope and Extended Lives for Patients
admin A kidney cancer diagnosis often ushers in a period of profound uncertainty, fear, and a...
biotech
Filspari’s Clearance in FSGS Marks End of Winding Regulatory Journey and Unlocks Over $1 Billion Annual Revenue Opportunity
The recent clearance of Filspari (sparsentan) by the U.S. Food and Drug Administration (FDA) for...
Spyre Therapeutics’ SPY001 Shows ‘Best-in-Class’ Potential in Ulcerative Colitis Trial, Shares Soar
Spyre Therapeutics, a prominent player in the inflammatory bowel disease (IBD) landscape, announced groundbreaking early...
Fourteenth Annual Keith A. Landesman Fundraiser Mobilizes Over $330,000 for Pioneering Cancer Immunotherapy Research.
This past February, the community of Sailfish Point in Stuart, Florida, once again convened for...
Menopause Emerges from the Shadows: Unpacking the $17 Billion Market Amidst Scientific Gaps and Systemic Underinvestment
The global health landscape is witnessing a profound shift as menopause, long relegated to hushed...
Major Overhaul of CDC’s ACIP Sparks Debate on Vaccine Policy, Concurrent with Key Biopharma Deals and RNA Therapeutic Advances
The Centers for Disease Control and Prevention (CDC) has formally published a new charter for...
Trailblazing Women: Celebrating Decades of Disruptive Innovation in Science and Cancer Research
During Women’s History Month, the Cancer Research Institute (CRI) proudly shines a spotlight on the...
Oricell Therapeutics Secures $110 Million in Pre-IPO Funding to Accelerate Groundbreaking Solid Tumor Cell Therapy Development
Shanghai-based Oricell Therapeutics, a burgeoning force in the biotechnology sector, has successfully closed a pre-initial...
Unlocking Immunotherapy’s Full Potential: Dr. Karin Pelka Pioneers AI-Driven Approach to Conquer Colorectal Cancer
Colorectal cancer (CRC), encompassing both colon and rectal cancers, represents a formidable challenge in modern...
FDA Rejects Replimune’s Melanoma Therapy Again Citing Unaddressed Study Concerns, Fueling Industry Debate
The U.S. Food and Drug Administration (FDA) has delivered a second significant blow to Replimune...
